RAD BioMed Accelerator is a venture capital firm that funds life sciences companies based in Israel.

RAD BioMed Accelerator

Broadview Ventures, Inc. (Broadview) was established in 2008 as a new program conceived by the Leducq family. Through Broadview, the trust will work to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investment in and support of early stage technology ventures.  The Foundation Leducq, based in Paris, France, is the beneficiary of a charitable trust. In order to further the Foundation Leducq's mission in cardiovascular and neurovascular disease, the trust has made funds available to Broadview to develop a program which will promote early state technology in these fields through investments, licensing agreements and consortium funding arrangements, as well as professional, management and consulting support.  With this initiative the trust joins other leaders in the venture philanthropy movement in seeking creative solutions to the problem of what is commonly referred to as the 'translational gap', a significant component of which is a lack of funding at a critical moment in the development of new technology and science.

Broadview Ventures

Go Capital & EOC (GEOC) is an investment firm that invests in Israeli high-tech companies in areas of life Sciences, 3D printing, AI, IOT, and etc. GEOC has experienced Chinese and Israeli teams with business and international expertise which is complementary in territory, domain and resources. In the past 20 years, the core teams of both China and Israel have been focusing on advancing those areas of interest. The Fund identified the growing potential in China – Israel relations in the political and economic arenas with complementary objectives and growing business opportunities. GEOC's vision is to be the innovation platform and growth engine for deep integration of advanced Israeli technology and Chinese manufacturing industry and huge market.

GEOC

Fresenius Medical Care is a provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1.89 million individuals worldwide. It has a network of 2,716 dialysis clinics in North America, Europe, Latin America, Asia-Pacific, and Africa.  It offers specialty pharmacy and laboratory services and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products, and renal pharmaceuticals. The company was founded in 1996 and is headquartered in Bad Homburg, Frankfurt.

Fresenius Medical Care

As a young and dynamic company with a spirit of entrepreneurship, we look first and foremost at the vision leading the entrepreneur. We believe that we should be investing in people, first and foremost. We strive to invest in companies led by entrepreneurs capable of envisioning and growing great companies with products and/or services meeting real market needs in large and growing markets. We seek companies with profound deep tech creating durable barriers to entry by the competition, thus gaining a sustainable hedge for the long-term and making a real impact on the world. We are less interested in companies whose products and/or services may become a commodity in short order. As a leading venture capital fund, Champel Capital’s responsibility accompanies every investment we make. Alongside our global standards for protecting social and environmental elements, we implement active Impact Investing as part of our asset allocation. It’s all about creating value, both financial and social. We like doing well by doing good, to all: our LPs, our companies and their founders and employees, our own employees, and of course, our partners. Our clients enjoy a wealth of flexibility. Investing in our Champel Capital Impact Deep Tech Fund grants the diversification and professional management of their capital in the Israeli VC space. Alternatively, our clients can opt to invest directly in specific companies through Champel Capital L.P.’s SPVs, with the luxury to pick and choose a precise investment. With this system, our LPs fully maintain their power of decision on every single deal, both in terms of ticket size and whether to add money on each subsequent round.

Champel Capital

Vectorious Medical Technologies

Vectorious Medical Technologies developed the V-LAP, the worlds first in-heart microcomputer which enables optimal treatment for heart failure patients, increasing their quality of life and life expectancy. The V-LAP sensory implant is the first digital, wireless, battery-less device that is able to communicate from deep within the body. It monitors the heart’s left atrium pressure (LAP) which has been proven to be the earliest, most accurate and effective predictor for heart failure deterioration. Vectorious is actively conducting clinical studies in Europe (Italy, Germany, UK and Israel) for the purpose of obtaining a CE mark. It is expected to launch a clinical study in the US in 2020.

Vectorious Medical Technologies is a Tel Aviv-based company founded in 2011. It has developed the V-LAP System, an implantable digital sensor that measures left atrial pressure (LAP) in the heart. The V-LAP sensor is implanted in the left atrial wall through a minimally invasive procedure, enabling remote monitoring of LAP levels. This data allows for early detection of fluid accumulation in heart failure patients before physiological symptoms appear.

V-LAP Allows Heart Failure Patients to Self-Adjust Medication: Vectorious Reports Promising Findings From its Pilot Study at the THT meeting

Vectorious Medical reports positive data from study of miniature heart sensor

First U.S. patient receives Vectorious Medical’s atrial pressure sensor implant

VECTOR-HF I Study Confirms Safety and Accuracy of V-LAP In-Heart Sensor for Left Atrial Pressure Management of Heart Failure

Lap System Gives More Power to HF Patients

Vectorious Begins the VECTOR-HF II Study of its Implantable In-Heart Sensor for Left Atrial Pressure-Guided Patient Self-Management of Heart Failure

Vectorious Announces VECTOR-HF I Study Confirms Safety and Accuracy of V-LAP In-Heart Sensor for Left Atrial Pressure Management of Heart Failure

Pushing the envelope in MedTech with emerging technologies

Next-gen Medical Devices

Vectorious Medical Technologies Announces First U.S. Patient Implanted with the V-LAP Left Atrial Pressure Sensor

Vectorious Medical Technologies is a Tel Aviv-based company founded in 2011. It has developed the V-LAP System, an implantable digital sensor that measures left atrial pressure (LAP) in the heart. The V-LAP sensor is implanted in the left atrial wall through a minimally invasive procedure, enabling remote monitoring of LAP levels. This data allows for early detection of fluid accumulation in heart failure patients before physiological symptoms appear.
The V-LAP System empowers patients to self-manage their condition by adjusting diuretic dosages based on their LAP readings through a dedicated app. In a pilot study presented in March 2023, patient self-management alone was sufficient to stabilize heart failure patients within optimal LAP thresholds for 89.1% of the follow-up duration. The study also reported a significant decrease in heart failure-related hospitalizations and improvements in quality of life metrics.
Vectorious has conducted multiple clinical studies evaluating the safety, accuracy, and efficacy of the V-LAP System. The VECTOR-HF I study, completed in November 2021 with 30 patients, confirmed the sensor's robust safety, ease of implantation, and accurate LAP measurement compared to pulmonary capillary wedge pressure data. Vectorious has reported implanting 56 V-LAP sensors across Europe, Israel, and the US, with over 40,000 days of LAP monitoring.

Convergent Dental, Inc. is a privately owned dental equipment and technology company. Its flagship product, Solea, is the only CO2 laser cleared by the FDA for all-tissue indications, delivering an anesthesia-free, blood-free, and suture-free experience for dentists and patients. Solea represents a breakthrough in dental laser technology, offering a distinct experience compared to traditional instruments or earlier laser treatments.
Solea is a novel 9.3-micron CO2 laser that nears the peak absorption of hydroxyapatite (enamel), enabling it to vaporize enamel with speed and precision. This unique wavelength, coupled with computer-controlled motors (galvos) that manipulate the beam thousands of times per second, allows dentists to perform procedures ranging from hard tissue to soft tissue with total control and efficiency.
A key feature of Solea is its variable-speed foot pedal, which lets dentists seamlessly transition from hard to soft tissue by adjusting the pressure applied. This intuitive design streamlines the learning curve for dentists accustomed to using a drill. Solea's three ergonomic handpieces – Contra-Angle, Straight, and Ultraguide – further enhance its versatility across various procedures.
Solea not only improves patient experiences but also offers practice benefits such as increased productivity, new patient flow, and efficiency gains. In October 2022, Convergent Dental received FDA clearance for Solea to aid in reducing mineral loss in dental enamel, protecting teeth against acid attack and caries development. This breakthrough application was commercially launched in November 2023 under the name Solea Protect.

Convergent Dental

Ossio is an orthopedic fixation technology company that has developed OSSIOfiber Intelligent Bone Regeneration Technology, a breakthrough implant material designed to securely fixate and fully integrate into the body's native anatomy without leaving any permanent hardware behind. This technology addresses the limitations of conventional metal and resorbable implants, combining unparalleled mechanical strength with natural bone healing.
Made from a proprietary mineral fiber matrix held together by a naturally degradable polymer, OSSIOfiber implants provide surgeons with a more biologically friendly way to restore patient stability and mobility. These implants are engineered to provide the strength required for functional fixation while allowing full integration into the native bone without adverse biological response.
Ossio's product portfolio includes compression screws, trimmable fixation nails, hammertoe fixation systems, suture anchors, and compression staples, all made with OSSIOfiber technology. These implants have received multiple FDA clearances since 2019, and the company has initiated commercialization of its products in the US. As of March 2022, over 6,000 implantations of OSSIOfiber products had been performed, demonstrating adoption of this innovative technology.
OSSIOfiber Intelligent Bone Regeneration Technology can address various surgical applications through the manufacturing of implant designs like nails, screws, staples, anchors, and plates. Ossio plans to pursue multiple applications in distal extremities, trauma, sports, reconstruction, pediatrics, and spine segments.
In February 2023, Ossio launched the world's first and only non-permanent compression staple made with OSSIOfiber technology, designed for predictable bone in-growth, regeneration, and replacement.

Ossio

Casana is a healthcare technology company that has developed the Heart Seat, an innovative toilet seat that enables effortless, integrated, and consistent in-home health monitoring. The Heart Seat is a replacement for a standard toilet seat and is designed to measure key clinical parameters such as heart rate, blood oxygen saturation (SpO2), and blood pressure.
In May 2023, Casana received FDA clearance for the Heart Seat to measure heart rate and SpO2 in adults aged 22 years and older, weighing between 90 to 350 pounds. The company plans to file for additional indications, including systolic and diastolic blood pressure, with the goal of launching the product in the market by the end of 2023.
The Heart Seat is equipped with sensors that passively capture health data whenever the seat is used, eliminating the need for user compliance or behavior changes. The data is automatically uploaded to the Casana Cloud, where it can be viewed by healthcare providers, enabling them to monitor patients' health trends and respond to changes in near real-time.
Casana's technology allows for the effortless collection of consistent and reliable data, assisting medical teams in monitoring chronic conditions beyond the hospital or physician's office. The company aims to unlock a new category in healthcare technologies that enables seamless, integrated, and continuous in-home health monitoring.
In January 2022, Casana was acquired by an undisclosed entity, further accelerating the commercialization of the Heart Seat.

Casana

Neurent Medical is a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, particularly chronic rhinitis. The company's flagship product is the NEUROMARK System, a device that received US Food and Drug Administration (FDA) 510(k) clearance in October 2021.
The NEUROMARK System is designed to gently apply controlled low-power radio frequency (RF) energy to target regions of the nasal cavity, disrupting the parasympathetic nerve signals that can trigger an inflammatory response. This alleviates chronic rhinitis symptoms such as persistent congestion, rhinorrhea (runny nose), swelling of the mucosal membrane, sneezing, and nasal itching. The system's unique flexible leaflet design and proprietary smart algorithms enable precise neurolysis (disruption) of the posterior nasal nerves (PNN) and accessory pathways, accommodating a range of patient anatomies while maintaining mucosal and vascular integrity.
Neurent Medical announced the limited market release of the NEUROMARK System in the US in February 2023, following the establishment of a new Category I Current Procedural Terminology (CPT) code by the American Medical Association (AMA) for PNN procedures, effective January 2024. The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) also endorsed the PNN procedure in 2023.

Neurent Medical

Genetesis is a medical imaging company specializing in biomagnetic cardiac imaging solutions. It has developed CardioFlux, a flagship magnetocardiography (MCG) system that non-invasively identifies myocardial ischemia, a condition where blood flow to the heart muscle is reduced. The technology measures the magnetic fields generated by the heart's electrical activity to detect ischemia within minutes, without using pharmaceuticals or radiation. CardioFlux MCG is designed to provide advanced imaging while prioritizing patient comfort.
The company's solutions target the diagnosis of coronary microvascular disease (CMD), a condition that has been challenging to identify due to a lack of effective functional diagnostics. By offering an accurate and rapid test for CMD, Genetesis aims to address an unmet clinical need and enable timely management of the condition.
In April 2023, the US Food and Drug Administration (FDA) granted CardioFlux MCG Breakthrough Device designation for the non-invasive diagnosis of myocardial ischemia in patients suspected of having CMD.
Genetesis was founded in 2013 and is headquartered in Mason, Ohio. The company has received over USD 40 million in funding to date, including a USD 17.5 million Series C round in October 2022. In April 2020, TDK Ventures, the corporate venture capital arm of TDK Corporation, invested in Genetesis, providing access to TDK's expertise in areas like biomagnetic sensors and magnetic noise suppression.

Genetesis

Companies that develop diagnostic devices used in a hospital setting to identify a disease, condition, or injury, such as imaging systems and endoscopes

Companies that develop implantable medical devices designed to be surgically placed inside the human body, either temporarily or permanently, including devices such as pacemakers, artificial joints, stents, and cochlear implants

Companies that develop non-surgical devices that are used in a procedure or intervention to cure or relieve a patient from an illness or disease such as laser treatments, dental equipment, and wound care management

Companies that develop monitoring devices that are used in a hospital setting to measure patient vital signs and ensure patient well-being post-treatment, such as cardiac and respiratory monitoring systems

Providers of software that enhances the functionality of medical device hardware (diagnosis, treatment, and monitoring)

Companies that develop surgical devices involving invasive interventions (cutting into a patient's body tissues) to treat, cure, or relieve a patient of an illness or disease

Companies that develop devices to administer pharmaceutical substances into a patient's body, ensuring controlled release or targeted delivery, specifically for use in clinical settings to treat or manage medical conditions effectively

Providers of software that helps manage risks, ensure quality, and streamline audit processes during medical device development

IoT connects devices to EHR systems for precise patient diagnosis and treatment support

Devices are linked to software platforms that use digital technologies such as AI/ML and VR

Startups leverage AI/ML and deep learning to support patient diagnosis and early detection

Vectorious Medical Technologies

Sources

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless